65.03
-0.63%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About PTC Therapeutics
From its filings with the US Securities and Exchange Commission
PTC Therapeutics is based in Warren, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker PTCT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $1.73bn and net income of $682.6m. At that date it held total assets of $2.90bn and shareholders' equity of −$205.3m.
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
Sephience is indicated for the treatment of adult and pediatric patients with PKU. Sephience has a novel dual mechanism of action. First, it is a natural precursor of the enzymatic co-factor BH4, a critical co-factor for phenylalanine hydroxylase (PAH), the enzyme affected in PKU. Sephience is able to serve as a more bioavailable source of intracellular BH4 than by administering BH4 itself. The second mechanism of action is Sephience’s ability to serve as an independent chaperone itself, stabilizing enzyme morphology and enhancing enzyme function. Through this dual mechanism of action, Sephience is able to effectively reduce blood Phe levels and has the potential to treat a broad range of PKU patients, including those with the most severe, non-BH4 responsive mutations.
Quoted from its 10-K, filed 19 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 20 Jun 2013
- Employees
- 991
- Website
- ptcbio.com ↗
- Head office
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael SchmertzlerIndependent Chairman of the Board$551,016
- Dr. Matthew KleinPresident, Chief Executive Officer, Director, since 2020$7.4m
- Mr. Pierre GravierChief Financial Officer$2.2m
- Dr. Neil AlmsteadChief Technical Operations Officer$2.3m
- Mr. Mark BouldingExecutive Vice President, Chief Legal Officer$2.2m
- Dr. Lee GoldenExecutive Vice President, Chief Medical Officer$2.2m
- Ms. Christine UtterSenior Vice President, Chief Accounting Officer, Head - People Services$1.7m
- Mr. Eric PauwelsChief Business Officer$2.4m
- Dr. Allan JacobsonIndependent Director$377,675
- Ms. Stephanie OkeyIndependent Director$302,175
- Ms. Emma ReeveIndependent Director$330,175
- Ms. Mary SmithIndependent Director$309,675
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 48
- Environment
- 24
- Social
- 62
- Governance
- 59
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- PTC Therapeutics Inc possesses several strengths that contribute to its competitive position and growth potential. These strengths include:
Weaknesses
- Despite its strengths, PTC Therapeutics Inc faces certain weaknesses that may impact its performance and market position. These weaknesses include:
Opportunities
- PTC Therapeutics Inc can leverage various opportunities to expand its market share and drive growth. These opportunities include:
Threats
- PTC Therapeutics Inc is exposed to several threats that may hinder its growth and competitiveness. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.